News
We have launched our flu campaign to vaccinate staff working closely with patients.
Opening in 2022, the Oak Cancer Centre (OCC) in Sutton will speed up the translation of world-leading research into breakthroughs in treatment and care, transforming the lives of cancer patients at The Royal Marsden and beyond.
Scientists at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (ICR) used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.
A novel tool designed by clinicians from The Royal Marsden has facilitated intensive care (ICU) patients to receive earlier access to palliative care. Use of the tool has increased referrals from intensive care unit (ICU) to palliative care by 46%, according to data from its first year of implementation in the hospital1.
The Royal Marsden NHS Foundation Trust has today marked a significant milestone in the construction of its new state-of-the-art treatment and research facility, the Oak Cancer Centre.
A pioneering trial to test if men with prostate cancer can safely receive radiotherapy in two large doses rather than smaller doses over five sessions has opened at The Royal Marsden NHS Foundation Trust.
In October 2020 Sophie was diagnosed with acute lymphoblastic leukaemia (ALL). Today she shares her story to help raise awareness of the disease during Childhood Cancer Awareness Month.
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
Results from a phase II randomised trial have shown that a combination of immunotherapy and a targeted therapy could extend time between treatments for some women with recurrent ovarian cancer.
Advanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.